Currently, cannabis is classified as a Schedule I substance, alongside drugs like heroin and LSD, which are considered to have a high potential for abuse and no accepted medical use. The proposal, under President Biden’s direction, suggests moving cannabis to Schedule III, indicating moderate to low dependence factors.

Experts have weighed in on the implications of this change. Dr. Kevin Sabet, President of Smart Approaches to Marijuana, expressed concerns about potential tax breaks for large companies. Meanwhile, JM Pedini, Development Director of NORML, argued that cannabis’s low abuse potential does not align with its current classification. The decision on rescheduling will be made by the DEA, DOJ, and Attorney General, with the possibility of a hearing or a direct decision by government officials.

Source: Wset.com